ATE296103T1 - Verminderung des infarktausmasses unter verwendung von citicolin - Google Patents

Verminderung des infarktausmasses unter verwendung von citicolin

Info

Publication number
ATE296103T1
ATE296103T1 AT96909616T AT96909616T ATE296103T1 AT E296103 T1 ATE296103 T1 AT E296103T1 AT 96909616 T AT96909616 T AT 96909616T AT 96909616 T AT96909616 T AT 96909616T AT E296103 T1 ATE296103 T1 AT E296103T1
Authority
AT
Austria
Prior art keywords
infarction
citicoline
extent
reducing
treatment
Prior art date
Application number
AT96909616T
Other languages
English (en)
Inventor
Bobby Winston Sandage
Marc Fisher
Kenneth W Locke
Original Assignee
Interneuron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE296103(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/603,102 external-priority patent/US5872108A/en
Priority claimed from US08/609,448 external-priority patent/US5827832A/en
Application filed by Interneuron Pharma filed Critical Interneuron Pharma
Application granted granted Critical
Publication of ATE296103T1 publication Critical patent/ATE296103T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96909616T 1995-03-06 1996-03-06 Verminderung des infarktausmasses unter verwendung von citicolin ATE296103T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39926295A 1995-03-06 1995-03-06
US08/603,102 US5872108A (en) 1995-03-06 1996-02-20 Reduction of infarct volume using citicoline
US08/609,448 US5827832A (en) 1995-03-06 1996-03-01 Method of protecting brain tissue from cerebral infarction subsequent to ischemia
PCT/US1996/003159 WO1996027380A1 (en) 1995-03-06 1996-03-06 Reduction of infarct volume using citicoline

Publications (1)

Publication Number Publication Date
ATE296103T1 true ATE296103T1 (de) 2005-06-15

Family

ID=27410335

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909616T ATE296103T1 (de) 1995-03-06 1996-03-06 Verminderung des infarktausmasses unter verwendung von citicolin

Country Status (14)

Country Link
EP (1) EP0813416B1 (de)
JP (1) JPH11511732A (de)
CN (2) CN1126546C (de)
AT (1) ATE296103T1 (de)
AU (1) AU5304796A (de)
BR (1) BR9607206A (de)
CA (1) CA2213000A1 (de)
DE (1) DE69634773T2 (de)
ES (1) ES2244968T3 (de)
MX (1) MX9706808A (de)
NO (1) NO313538B1 (de)
PL (1) PL185124B1 (de)
PT (1) PT813416E (de)
WO (1) WO1996027380A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
AU1944799A (en) * 1997-12-24 1999-07-19 Interneuron Pharmaceuticals, Inc. Hyperhydrated citicoline, process and use
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
ES2169986B1 (es) * 2000-03-14 2003-06-16 Ferrer Int Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
PL370371A1 (en) 2001-10-15 2005-05-16 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
ES2345802B1 (es) * 2009-03-30 2011-09-08 Hospital Clinic I Provincial De Barcelona Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus.
RU2595857C2 (ru) 2012-05-31 2016-08-27 Кинки Юниверсити Средство для профилактического и/или терапевтического лечения периферической нейропатической боли, вызываемой противораковым средством
ES2906614T3 (es) * 2012-10-30 2022-04-19 Kyowa Hakko Bio Co Ltd Agente para evitar o mejorar el deterioro de la función cerebral
CN105769882B (zh) * 2016-03-14 2019-02-22 北京赛德维康医药研究院 一种抑制血栓形成的药物组合物及其用途
US10709710B2 (en) 2017-05-09 2020-07-14 Hospital Clinic De Barcelona Composition comprising uric acid for the treatment treated with mechanical thrombectomy
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
IT1207106B (it) * 1980-04-18 1989-05-17 Made Italiana Srl Ora Searle I Preparazione farmaceutica contenente citidin disfofocolina assorbibile per via orale

Also Published As

Publication number Publication date
NO974076D0 (no) 1997-09-04
EP0813416A1 (de) 1997-12-29
ES2244968T3 (es) 2005-12-16
DE69634773T2 (de) 2006-05-04
DE69634773D1 (de) 2005-06-30
CN1126546C (zh) 2003-11-05
EP0813416B1 (de) 2005-05-25
CN1181015A (zh) 1998-05-06
MX9706808A (es) 1998-08-30
JPH11511732A (ja) 1999-10-12
BR9607206A (pt) 1997-11-11
CA2213000A1 (en) 1996-09-12
CN1488353A (zh) 2004-04-14
PT813416E (pt) 2005-10-31
AU5304796A (en) 1996-09-23
NO313538B1 (no) 2002-10-21
NO974076L (no) 1997-10-28
EP0813416A4 (de) 2000-11-15
PL185124B1 (pl) 2003-02-28
PL322061A1 (en) 1998-01-05
WO1996027380A1 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
ATE296103T1 (de) Verminderung des infarktausmasses unter verwendung von citicolin
EP0299602A3 (en) Use of indolone derivatives for the treatment of parkinsons disease
HK1005740A1 (en) Acylated uridine and cytidine and uses thereof
KR960702318A (ko) 근육 질병 및 장애의 치료방법
DE60115618D1 (de) Verwendung von kosmetische und pharmazeutische zubereitungen enthaltend 2-decarboxy-2-phosphino prostaglandinderivate
DK0665749T3 (da) Sammensætning til behandling af Parkinsons sygdom
ATE153855T1 (de) Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
BG97068A (bg) Фармацевтичен състав и метод за постигане на терапевтичен ефект
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
EP0985671A4 (de) PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
DK0614456T3 (da) 1alfa,24(S)-dihydroxy-vitamin D2, dets fremstilling og anvendelse
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
DK455088D0 (da) Syntetiske receptoranaloger
GB9410639D0 (en) Method of improving fertilization
MXPA04004826A (es) Antagonista del receptor de quimioquinas y metodos para su uso.
EP0299050A4 (de) Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.
NO953573L (no) Benzopyraner som kaliumkanalåpnere
DE3574675D1 (de) Verfahren zum sterilisieren von rekombinantem mikroorganismus.
MY107336A (en) The process for the preparation of enantiomerically pure thienopyran derivatives.
ATE221381T1 (de) Fungizide, hautkosmetishe zusammensetzung
UA31556A (uk) Спосіб профілактики мозкової ішемії під час рентгеноконтрастних та інструментальних досліджень магістральних судин голови
DE19681129D2 (de) Verwendung des alpha,alpha-Diphenylessigsäure-4-(N-Methyl-Piperidyl)esters als Spasmoanalgetikum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties